Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration

BACKGROUND: Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatra...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am Heart J
Главные авторы: Shore, Supriya, Carey, Evan P., Turakhia, Mintu P., Jackevicius, Cynthia A., Cunningham, Fran, Pilote, Louise, Bradley, Steven M., Maddox, Thomas M., Grunwald, Gary K., Barón, Anna E., Rumsfeld, John S., Varosy, Paul D., Schneider, Preston M., Marzec, Lucas N., Ho, P. Michael
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381802/
https://ncbi.nlm.nih.gov/pubmed/24890529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2014.03.023
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы